A recall of certain compounded veterinary medications highlights how laboratory analytical reliability can become a patient-safety issue even when no contamination has been identified. On October 21, the U.S. Food and Drug Administration posted a company announcement from Wedgewood Pharmacy concerning products that may be subpotent or superpotent.
The recall covers a wide range of compounded veterinary products. According to the announcement, the affected formats include:
Powders and pastes
Oral suspensions
Injectables
Ophthalmic ointments and solutions
Ear solutions and suspensions
Topical sprays and gels
The products have no brand name and are described only as compounded veterinary medications. Because the list is long, the company has published a full lookup of affected products, lot numbers and expiration dates at www.wedgewood.com/recall-lookup/. The FDA notice does not list individual lots, so anyone with a Wedgewood product should check that page directly.
According to the notice, the recall was initiated because of inconsistencies in the reliability of analytical testing data generated by the company's laboratory. Affected products were shipped in the United States between February 18 and October 6, 2026. The products span several dosage forms, including oral preparations, injectables, ophthalmic products and topical formulations. The products involved are intended for companion, equine, exotic, zoo, wildlife, and aquatic animals. They are not intended for use in food-producing animals.
The company reported 98 complaints, including seven characterized as serious, at the time of the announcement. Those are reported complaint figures, not a verified count of adverse reactions causally linked to potency errors. The FDA page explicitly states that it publishes company recall announcements as a public service and does not endorse the products or company.
For laboratory managers, the event illustrates why potency testing requires more than an instrument result. Method suitability, calibration, reference materials, data integrity, sample traceability and review of unexpected analytical patterns all contribute to confidence in a release decision. When the reliability of those controls is questioned, the implications may extend across multiple formulations and lots.
The company directed veterinary practices and other customers to identify and quarantine affected inventory and follow its recall process. Product-specific instructions and the current lot list should be obtained from the official recall lookup rather than inferred from a broad product category. This is a quality-system story with immediate operational implications; it should not be portrayed as proof that every product made by the manufacturer is defective.